Who Paid My Doc
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis
ClinicalTrials.gov NCT05862272
Research payments
$10,615,412
Through program year 2025, $10,615,412 in research payments was reported against A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis, across 3,011 payments, paid by Sumitomo Pharma America, Inc..
- Paid by
- Sumitomo Pharma America, Inc.
- ClinicalTrials.gov
- NCT05862272
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $4,924,794 | 1,581 |
| 2024 | Research | $5,121,546 | 1,285 |
| 2023 | Research | $569,072 | 145 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Stephanie Slocum Dallas, TX Named on 366 payments
- Brian MacGillivray San Antonio, TX Named on 171 payments
- Dawnette Peppler Arlington, TX Named on 98 payments
- Mark Jacobs Houston, TX Named on 60 payments
- Brandon Perez Marrero, LA Named on 51 payments
- Michael Johnson Lakewood, CO Named on 49 payments
- Tifany Nolan Batavia, OH Named on 45 payments
- Ramin Farsad Encinitas, CA Named on 44 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.